Qilu Pharmaceutical Co., Ltd.

Jul 07, 2025

Sagent and Qilu Announce Strategic Collaboration to Expand Access to Critical Injectables in U.S.

Dec 25, 2024

Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting

Sep 10, 2024

Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024

Mar 15, 2024

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

Mar 04, 2024

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

Feb 02, 2024

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

Jan 30, 2024

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology